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This post hoc analysis was conducted to evaluate the efficacy, tolerability, and health-related quality of life during
long-term adjunctive brivaracetam (BRV) treatment in adult patients with focal to bilateral tonic-clonic seizures
(FBTCS). Patients (≥ 16 years) were included in this post hoc analysis if they were randomized to BRV or placebo in
double-blind, placebo-controlled (N01252 [NCT00490035], N01253 [NCT00464269], N01358 [NCT01261325];
core) trials, and received adjunctive BRV in the corresponding long-term follow-up (N01125 [NCT00175916],
N01199 [NCT00150800], N01379 [NCT01339559]) trials, and reported FBTCS during the 8-week prospective
baseline (core trial). Efficacy (concomitant levetiracetam excluded) and tolerability (concomitant levetiracetam
included) were assessed from the first day of BRV in patients who initiated BRV at 50–200 mg/day.
Two hundred and eighty-four patients reported FBTCS during baseline (core trials) and were included in the
Efficacy Set. Patients (mean age of 37.0 years; 51.8% male; mean epilepsy duration of 22.4 years; median
baseline frequency of 2.8 FBTCS per 28 days) received BRV for a median treatment duration of 2.5 years (range<
0.1–11.3) at a median modal dose of 150 mg/day. BRV was discontinued by 175 (61.6%) patients, most
commonly (≥ 10% of patients) due to adverse event (18.3%), lack of efficacy (18.3%), and consent withdrawn
(11.6%); the median time to discontinuation of BRV due to any reason was 358.5 days. The Kaplan-Meier (KM)estimated retention on BRV at 1, 3, and 5 years, were 69.3%, 48.2%, and 37.3%, respectively. The KM-estimated
proportion of patients not discontinuing BRV due to lack of efficacy or adverse event were 80.0%, 63.9%, and
57.2% at 1, 3, and 5 years, respectively. Overall, the median percentage reduction in FBTCS frequency from
baseline was 76.2%, and the 50% and 75% responder rates for FBTCS were 68.7% and 50.7%, respectively,
which were sustained over time across completer cohorts. Sustained 50%, 75%, and 100% response in FBTCS
from day 1 of adjunctive BRV treatment during the entire first year was estimated for 32.5%, 21.1%, and 15.0%
of patients, respectively (KM analysis), and showed maintenance or improvement in the response to BRV over
time. For patients with ≥ 1 year of BRV exposure, 51.3% were free from FBTCS for ≥ 1 year during any time of
the treatment period, and 22.8% of patients did not report FBTCS during the first year from the first day of
treatment. Clinically meaningful improvements in total Patient Weighted Quality of Life in Epilepsy InventoryForm 31 (QOLIE-31-P) score were reported by 43.6% and 46.4% of patients after 1 and 2 years of treatment,
respectively. The largest improvements in the QOLIE-31-P score, with > 50% of patients reporting a clinically
meaningful improvement, were observed in the seizure worry and daily activities/social functioning subscales
after 1 and 2 years of BRV treatment. Overall, 278/313 (88.8%; Safety Set) patients reported at least one

Abbreviations: AE, adverse event; ASM, antiseizure medication; BRV, brivaracetam; CI, confidence interval; ES, Efficacy Set; FBTCS, focal to bilateral tonic-clonic
seizures; HRQoL, health-related quality of life; KM, Kaplan-Meier; QOLIE-31-P, Patient Weighted Quality of Life in Epilepsy Inventory-Form 31; SD, standard de
viation; SS, Safety Set; SUDEP, sudden unexpected death in epilepsy; SV2A, synaptic vesicle protein 2A; TEAE, treatment-emergent adverse event.
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treatment-emergent adverse event (TEAE), 170 (54.3%) had a drug-related TEAE, 88 (28.1%) had a serious
TEAE, and 55 (17.6%) discontinued BRV due to a TEAE.
Overall, long-term adjunctive BRV was generally well tolerated and reduced the frequency of FBTCS in adults,
with 22.8% of patients (who completed ≥ 1 year of treatment) not reporting any FBTCS during the first year from
the first day of BRV treatment.

1. Introduction

(whether or not they had other types of seizures), and initiated BRV at a
dose 50–200 mg/day (the approved therapeutic dose range for adults)
during either the core or long-term follow-up trial. Data for patients who
received BRV during a double-blind trial and did not enroll in a longterm follow-up trial were included in the analysis. Efficacy and tolera
bility were assessed from the first day of BRV treatment in patients
randomized to BRV in the core trial, and from the first day in the longterm follow-up trial in patients randomized to placebo in the core trial
(the last visit of the core trial was classified as the start of the long-term
follow-up trial).

Brivaracetam (BRV) is an antiseizure medication (ASM) with high
and selective affinity for synaptic vesicle protein 2A (SV2A) in the brain,
with a 15- to 30-fold higher affinity than levetiracetam (Gillard et al.,
2011; Matagne et al., 2008). BRV is indicated as monotherapy (in the
United States) and as adjunctive treatment (in the United States and
European Union) of focal seizures with or without focal to bilateral
tonic-clonic seizures (FBTCS; secondary generalized seizures) in patients
4 years of age and older (UCB Inc, 2018; UCB Pharma, 2020). BRV is also
approved in multiple other regions globally, including several countries
across the Asia Pacific region and North and South America.
Patients with tonic-clonic seizures have a greater risk of injury and
falls (Lawn et al., 2004), higher mortality (Lhatoo et al., 2001), higher
risk of sudden unexpected death in epilepsy (SUDEP) (Devinsky, 2011;
Hirsch et al., 2011; Laxer et al., 2014; Shorvon and Tomson, 2011), and
worse quality of life (Viteva, 2014), compared to patients with other
seizure types. Tonic-clonic seizure frequency has been reported as the
most important risk factor for SUDEP (Shorvon and Tomson, 2011).
Importantly, in patients with drug-resistant seizures, reducing
tonic-clonic seizure frequency to two or fewer seizures per year after
epilepsy surgery has been associated with a significant reduction in
mortality, comparable with that for patients who are entirely seizure
free (Sperling et al., 2016). Therefore, it is important to reduce the
frequency and burden of FBTCS, in order to reduce morbidity and
mortality of people with epilepsy, and improve their quality of life.
Previous post hoc analyses of pooled data from three double-blind,
placebo-controlled, fixed-dose Phase III trials showed that adjunctive
BRV 50–200 mg/day reduced the frequency of FBTCS over 12 weeks in
patients with FBTCS at baseline, with higher level of response generally
observed with higher BRV doses (Moseley et al., 2016). The majority of
patients with FBTCS who achieved 75–100% sustained seizure fre
quency reduction with oral BRV (100 or 200 mg/day) achieved this
response from the first day of BRV treatment (Klein et al., 2020a).
The aim of this analysis was to evaluate the long-term efficacy,
tolerability, and health-related quality of life (HRQoL) of adjunctive
BRV in adult patients with FBTCS, by exploring pooled data from the
three aforementioned double-blind Phase III trials of adjunctive BRV
and the corresponding open-label, long-term follow-up trials.

2.2. Outcomes and statistical analysis
Efficacy outcomes were assessed in patients randomized to BRV or
placebo (core trial) who had at least one post-baseline seizure diary entry
during adjunctive BRV treatment, excluding those taking concomitant
levetiracetam during the core or long-term follow-up trials (Efficacy Set;
ES). Efficacy data were also analyzed in completer cohorts comprising
patients who received BRV and had seizure diary data for the specified
duration across the core and long-term follow-up trials combined. For
example, patients completing at least 1 year of BRV treatment were
included in the 1-year completer cohort, with 1 year defined as 52 weeks or
364 days. The frequency of FBTCS was standardized to 28 days.
Efficacy outcomes included percentage reduction from baseline (core
trials) in FBTCS frequency per 28 days, and 50% and 75% responder
rates (patients with a ≥ 50% or ≥ 75% reduction in FBTCS frequency
from baseline, respectively), analyzed for the overall population and by
BRV modal dose, yearly completer cohorts, number of prior ASMs
(discontinued before BRV initiation), number of concomitant ASMs at
BRV initiation, age at epilepsy onset, and epilepsy duration; time to
50%, 75%, and 100% sustained response in FBTCS during the first year
of BRV treatment (overall and by BRV modal dose category); freedom
from FBTCS by yearly completer cohort; and the proportion of patients
reporting none, or one to two FBTCS by yearly completer cohort and
time interval. The number of days with FBTCS per patient per 8 weeks
during the 8-week baseline and by 8-week intervals during BRV treat
ment were also analyzed for the overall population, by 50% responder
status, and by yearly completer cohorts. The time from baseline start to
the first FBTCS during baseline, the time from the last FBTCS before BRV
initiation to BRV initiation, and the time from BRV initiation to the first
FBTCS were also assessed.
The probability of patients who achieved sustained responder status
during the first year of BRV treatment was estimated by the KaplanMeier (KM) method. Patients were classified as sustained 50%, 75%,
or 100% responders on a particular day if they completed the entire
period through day 364 and were a ≥ 50%, ≥ 75%, or 100% responder
(based on percentage reduction in FBTCS frequency from baseline) both
on that day and for every successive day through day 364. Patients who
discontinued treatment before day 364 were classified as non
responders; by definition, these patients never achieved a sustained
responder status.
For assessments of continuous freedom from FBTCS, patients were
defined as FBTCS-free if they had a period of consecutive days with no
FBTCS for at least 1, 2, 3, 4, or 5 years at any time during BRV treatment,
and the seizure diary was completed for at least 90% of days within the
specified BRV treatment interval. Assessment of the proportion of pa
tients not reporting FBTCS or reporting one to two FBTCS per year of
BRV treatment was also assessed in the yearly completer cohorts.

2. Methods
2.1. Trials and populations
In the core, 12-week, fixed-dose, Phase III trials (N01252
[NCT00490035] (Ryvlin et al., 2014), N01253 [NCT00464269] (Biton
et al., 2014), N01358 [NCT01261325] (Klein et al., 2015)), adult pa
tients (≥ 16 years) with focal seizures were randomized to placebo or
BRV 5, 20, 50, 100, or 200 mg/day, in addition to one or two other
ASMs. Patients who subsequently entered a corresponding long-term
follow-up trial (N01125 [NCT00175916] (Ben-Menachem et al.,
2021), N01199 [NCT00150800] (O’Brien et al., 2020), N01379
[NCT01339559] (Toledo et al., 2021)) were allowed to receive BRV up
to 200 mg/day. The treatment duration in the long-term follow-up trials
ranged from up to 8 years in N01379 to up to 14 years in N01125.
Post hoc efficacy, tolerability, and HRQoL analyses were completed
using data from patients who received placebo or BRV in each core trial,
had FBTCS during the 8-week prospective baseline of the core trial
2
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compared with the other groups. Of the 284 patients (ES) with baseline
FBTCS, 253 (89.1%) entered one of the long-term follow-up trials of
BRV.

Tolerability outcomes were assessed in patients who initiated BRV at
50–200 mg/day, including patients taking concomitant levetiracetam
(Safety Set; SS). Tolerability outcomes included treatment-emergent
adverse events (TEAEs), TEAEs considered drug-related, severe TEAEs,
serious TEAEs, discontinuations due to adverse events (AEs), psychiatric
TEAEs, TEAEs potentially associated with behavioral disorders, and
deaths. AEs were coded using the Medical Dictionary for Regulatory
Activities (MedDRA) Version 15.0 (www.meddra.org, March 2012).
Signs or symptoms of epilepsy were recorded as TEAEs only if their
nature changed considerably or their frequency or intensity increased in
a clinically significant manner as compared to the clinical profile known
to the investigator from the patient’s history or baseline period. Re
ported TEAEs were not considered as adverse drug reactions, and as such
not attributed to BRV by default. Therefore, seizure worsening episodes
would not be automatically considered BRV related. Psychiatric TEAEs
were classified using the MedDRA System Organ Class “Psychiatric
disorders”. TEAEs associated with behavioral disorders were based on
the medical review of the MedDRA dictionary of Preferred Terms. The
Preferred Terms associated with behavioral disorders reported by more
than one patient included irritability, aggression, abnormal behavior,
agitation, and anger.
The change from baseline, and proportion of patients with a clini
cally meaningful improvement from baseline, in Patient Weighted
Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) total score
and subscale scores (Cramer et al., 2003) after 1 and 2 years of
adjunctive BRV treatment were assessed in the ES. QOLIE-31-P is a
patient-reported epilepsy-specific HRQoL instrument (scored 0–100;
higher scores represent better functioning). A clinically meaningful
improvement in QOLIE-31-P was defined as a change from baseline of
greater than 5.19 points for the total score, and for the subscale scores, a
change from baseline of greater than 7.42 for seizure worry, 3.95 for
daily activities/social function, 5.25 for energy/fatigue, 4.76 for
emotional well-being, 5.34 for cognitive function, 5.00 for medication
effects, and 6.42 for overall quality of life (Borghs et al., 2012). For
patients taking BRV during the core trial, the QOLIE-31-P time points
were 1 and 2 years plus 84 days.
An analysis was conducted to determine the time from BRV initiation
to first FBTCS or first TEAE of grand mal convulsion during BRV treat
ment in patients with no history of FBTCS.
Due to the post hoc nature of this analysis, and the observational
nature of the long-term follow-up trials, no formal statistical testing was
conducted. The time to discontinuation due to any reason, lack of effi
cacy, AEs, or lack of efficacy or AEs, and the time to sustained response
during the first year of BRV treatment were estimated by the KM
method.

3.2. BRV dosing, treatment duration, and patient disposition
Patients received BRV at a median modal dose of 150 mg/day (range
20–200 mg/day) for a median treatment duration of 2.5 years (range <
0.1–11.3 years; ES). In the SS (n = 313), the proportion of patients with a
modal dose of BRV ≤ 100, > 100 to < 200, and 200 mg/day, was 31.6%,
30.0%, and 38.3%, respectively. The proportion of patients in the ES
with a modal dose of BRV ≤ 100, > 100 to < 200, and 200 mg/day, was
30.3%, 29.2%, and 40.5%, respectively, with a median treatment
duration of 0.9 years, 2.8 years, and 2.8 years, respectively (ES). The
overall median starting dose was 100 mg/day (n = 284; ES); for patients
with a modal dose of BRV ≤ 100, > 100 to < 200, and 200 mg/day, the
median starting dose of BRV was 75 mg/day, 75 mg/day, and 150 mg/
day, respectively.
One hundred and seventy-five (61.6%) patients discontinued BRV.
The main reasons for discontinuation (≥ 10% of patients) overall were
AE (52 [18.3%]), lack of efficacy (52 [18.3%]), and consent withdrawn
(33 [11.6%]) (Supplementary Fig. 1). During the first year of BRV
treatment, 91 (32.0%) patients discontinued; the main reasons (≥ 5% of
patients) for BRV discontinuation in the first year were AE (12.0%) and
lack of efficacy (7.0%). A higher proportion of patients with a BRV
modal dose of ≤ 100 mg/day discontinued due to AE, with the majority
discontinuing during the first year of BRV treatment, compared to pa
tients with higher BRV modal doses (Supplementary Fig. 1).
The KM-estimated time to discontinuation of BRV due to AE or lack
of efficacy were generally similar, with a slightly higher proportion of
patients discontinuing due to AE during the initial months of BRV
treatment (Supplementary Fig. 2). Overall, the median time to discon
tinuation of BRV due to any reason was 358.5 (range 2–2754) days, due
to lack of efficacy was 446.5 (range 34–1957) days, due to AE was 196.5
(range 2–2754) days, and due to lack of efficacy or AE was 343.5 (range
2–2754) days. During the first year of BRV treatment, the overall median
time to BRV discontinuation was 144 days; it was shorter in patients
with a BRV modal dose ≤ 100 mg/day (106 days) compared to those
with a BRV modal dose of > 100 to < 200 mg/day (183 days) or 200 mg/
day (207 days).
The KM-estimated proportion of patients remaining on BRV treat
ment at 1, 3, and 5 years, were 69.3%, 48.2%, and 37.3%, respectively.
The KM-estimated proportion of patients not discontinuing BRV due to
lack of efficacy at 1, 3, and 5 years, were 91.5%, 78.5%, and 73.1%. The
KM-estimated proportion of patients not discontinuing BRV due to AE at
1, 3, and 5 years, were 87.4%, 81.4%, and 78.3%. The KM-estimated
proportion of patients not discontinuing BRV due to lack of efficacy or
AE at 1, 3, and 5 years, were 80.0%, 63.9%, and 57.2%.

3. Results
3.1. Baseline characteristics
Overall, a total of 313 patients reported FBTCS during baseline and
initiated BRV at 50–200 mg/day and were included in the SS, including
a small number of patients (n = 29) taking concomitant levetiracetam. In
the ES (which excluded patients taking concomitant levetiracetam), 284
patients reported FBTCS during baseline and initiated BRV 50–200 mg/
day. At baseline, patients in the ES had a mean (standard deviation [SD])
age of 37.0 (12.5) years and a mean (SD) epilepsy duration of 22.4
(12.8) years; 51.8% were male (Table 1).
In the overall ES, the median baseline FBTCS frequency was 2.8
seizures per 28 days. Patients in the BRV ≤ 100 mg/day modal dose
group had a higher median baseline FBTCS frequency (3.5/28 days)
compared with patients on higher BRV modal doses (> 100 to < 200
mg/day: 3.0/28 days; 200 mg/day: 2.0/28 days).
At BRV initiation, patients were taking a mean (SD) of approximately
two (0.5) concomitant ASMs. A slightly higher proportion of the BRV
200 mg/day modal dose group had only one concomitant ASM

3.3. Efficacy of BRV overall, by modal dose, and by completer cohort
The median percentage reduction in FBTCS frequency from baseline was
76.2%. The 50% and 75% responder rates in FBTCS were 68.7% and 50.7%,
respectively. In the overall FBTCS population, the median percentage FBTCS
reduction, 50% responder rate, and 75% responder rate were numerically
lower in patients with a BRV modal dose ≤ 100 mg/day than those with
higher BRV modal doses.
In the 1-year (n = 193), 2-year (n = 158), 3-year (n = 116), 4-year
(n = 70), and 5-year (n = 43) completer cohorts, the median percentage
reductions in FBTCS frequency from baseline (core trial) were 77.4%,
82.0%, 86.3%, 88.3%, and 90.5%, respectively (Fig. 1A). The 50%
responder rates were 75.1%, 77.2%, 78.4%, 80.0%, and 79.1% (Fig. 1B).
The 75% responder rates were 53.4%, 58.2%, 62.1%, 62.9%, and 65.1%
(Fig. 1C). In each completer cohort the efficacy of BRV was maintained
over time (Supplementary Fig. 3).
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Efficacy Set excluding patients on concomitant LEV

Safety Set including patients on concomitant LEV

BRV modal dose category

BRV Overall (N
= 284)

BRV ≤ 100 mg/
day (n = 86)

BRV > 100 to < 200
mg/day (n = 83)

BRV 200 mg/day
(n = 115)

BRV Overall (N
= 313)

BRV ≤ 100 mg/
day (n = 99)

BRV > 100 to < 200
mg/day (n = 94)

BRV 200 mg/day
(n = 120)

Age, mean (SD), years
Male, n (%)
Age at onset of epilepsy, mean (SD), years
Duration of epilepsy, mean (SD), years
Baseline focal seizure frequency per 28 days, median
(range)
Baseline FBTCS frequency per 28 days, median (range)

37.0 (12.5)
147 (51.8)
15.1 (13.0)
22.4 (12.8)
8.3
(2.9–494.2)
2.8
(0.4–41.1)

36.1 (12.7)
46 (53.5)
14.5 (13.9)
22.2 (11.9)
9.7
(3.8–135.5)
3.5
(0.4–41.1)

37.6 (13.1)
42 (50.6)
14.8 (12.6)
23.4 (13.3)
7.1
(3.6–143.8)
3.0
(0.4–25.3)

37.2 (11.9)
59 (51.3)
15.9 (12.6)
21.8 (13.1)
8.0
(2.9–494.2)
2.0
(0.4–27.5)

37.3 (12.6)
161 (51.4)
15.0 (13.0)
22.9 (13.2)
8.5
(2.9–494.2)
2.8
(0.4–41.1)

36.6 (12.8)
53 (53.5)
14.2 (13.8)
23.0 (12.6)
9.4
(3.6–135.5)
3.3
(0.4–41.1)

37.6 (13.0)
48 (51.1)
14.7 (12.5)
23.5 (13.3)
7.1
(3.5–143.8)
3.0
(0.4–25.3)

37.6 (12.1)
60 (50.0)
15.9 (12.8)
22.3 (13.5)
8.0
(2.9–494.2)
2.0
(0.4–27.5)

52 (18.3)
28 (9.9)

19 (22.1)
8 (9.3)

18 (21.7)
8 (9.6)

15 (13.0)
12 (10.4)

57 (18.2)
30 (9.6)

19 (19.2)
9 (9.1)

22 (23.4)
8 (8.5)

16 (13.3)
13 (10.8)

149 (52.5)

39 (45.3)

47 (56.6)

63 (54.8)

167 (53.4)

48 (48.5)

54 (57.4)

65 (54.2)

55 (19.4)

20 (23.3)

10 (12.0)

25 (21.7)

59 (18.8)

23 (23.2)

10 (10.6)

26 (21.7)

Number of prior ASMsc, n (%)
0–1
2–4
≥5

77 (27.1)
110 (38.7)
97 (34.2)

22 (25.6)
38 (44.2)
26 (30.2)

33 (39.8)
28 (33.7)
22 (26.5)

22 (19.1)
44 (38.3)
49 (42.6)

81 (25.9)
126 (40.3)
106 (33.9)

24 (24.2)
44 (44.4)
31 (31.3)

33 (35.1)
36 (38.3)
25 (26.6)

24 (20.0)
46 (38.3)
50 (41.7)

Number of concomitant ASMs at BRV initiationd, n (%)
0
1
2
≥3

1 (0.4)
69 (24.3)
208 (73.2)
6 (2.1)

1 (1.2)
18 (20.9)
64 (74.4)
3 (3.5)

0
18 (21.7)
64 (77.1)
1 (1.2)

0
33 (28.7)
80 (69.6)
2 (1.7)

1 (0.3)
73 (23.3)
232 (74.1)
7 (2.2)

1 (1.0)
19 (19.2)
75 (75.8)
4 (4.0)

0
20 (21.3)
73 (77.7)
1 (1.1)

0
34 (28.3)
84 (70.0)
2 (1.7)

Concomitant ASMs at BRV initiation, taken by ≥ 10 of all patients, n (%)
Carbamazepine
109 (38.4)
Valproate
93 (32.7)
Lamotrigine
63 (22.2)
Oxcarbazepine
46 (16.2)
Topiramate
38 (13.4)
Phenytoin
36 (12.7)

30 (34.9)
32 (37.2)
16 (18.6)
15 (17.4)
12 (14.0)
12 (14.0)

35 (42.2)
28 (33.7)
19 (22.9)
14 (16.9)
12 (14.5)
11 (13.3)

44 (38.3)
33 (28.7)
28 (24.3)
17 (14.8)
14 (12.2)
13 (11.3)

118 (37.7)
97 (31.0)
70 (22.4)
51 (16.3)
42 (13.4)
39 (12.5)

33 (33.3)
34 (34.3)
19 (19.2)
18 (18.2)
13 (13.1)
14 (14.1)

38 (40.4)
30 (31.9)
20 (21.3)
16 (17.0)
13 (13.8)
12 (12.8)

47 (39.2)
33 (27.5)
31 (25.8)
17 (14.2)
16 (13.3)
13 (10.8)

BRV initiation period
Core trial, n (%)
Long-term follow-up trial, n (%)
Patient entered long-term follow-up trial, n (%)
Concomitant LEV at BRV initiation, n (%)
Concomitant LEV at any time during the trial, n (%)

79 (91.9)
7 (8.1)
66 (76.7)
–
–

59 (71.1)
24 (28.9)
83 (100)
–
–

91 (79.1)
24 (20.9)
104 (90.4)
–
–

254 (81.2)
59 (18.8)
280 (89.5)
17 (5.4)
29 (9.3)

91 (91.9)
8 (8.1)
77 (77.8)
10 (10.1)
13 (13.1)

68 (72.3)
26 (27.7)
94 (100)
7 (7.4)
11 (11.7)

95 (79.2)
25 (20.8)
109 (90.8)
0
5 (4.2)

Seizure classificationb, n (%)
Secondary generalized (FBTCS) only
Secondary generalized (FBTCS) and simple partial
(focal aware)
Secondary generalized (FBTCS) and complex partial
(focal impaired awareness)
Secondary generalized (FBTCS), simple partial (focal
aware), and complex partial (focal impaired
awareness)

B.D. Moseley et al.

Table 1
Baseline demographics and epilepsy characteristics overall and by BRV modal dose categorya.

4

ASM, antiseizure medication; FBTCS, focal to bilateral tonic-clonic seizures; LEV, levetiracetam; SD, standard deviation.
a
Patients with an initial BRV dose of 50–200 mg/day during either the core or long-term follow-up trial.
b
Seizure types are listed per the International League Against Epilepsy 1981 classification (Commission on Classification and Terminology of the International League Against Epilepsy, 1981) as per the trial protocol,
with the newer terminology (Fisher et al., 2017) provided in parentheses.
c
Prior ASMs were ASMs discontinued before BRV initiation (in the core or long-term follow-up trial). Trials N01252 and N01253 collected ASM use within the 5 years before trial entry, whereas trial N01358 collected all history
of ASMs used before trial entry.
d
One patient randomized to placebo (N01252) was taking lamotrigine and oxcarbazepine that were discontinued 9 days before BRV initiation and recommenced on the day of BRV initiation.
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229 (80.6)
55 (19.4)
253 (89.1)
–
–
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Fig. 1. Efficacy of BRV for the overall population and yearly completer cohorts by BRV all dosages and modal dose: (A) median percentage reduction from baseline of
the core trial in FBTCS frequency per 28 days, (B) 50% responder rate, and (C) 75% responder rate (ES).
BRV, brivaracetam; ES, Efficacy Set; FBTCS, focal to bilateral tonic-clonic seizures.

3.4. Time to sustained response during the first year of adjunctive BRV
treatment

of patients achieving sustained 100% response in FBTCS was stable from
the day 1 to day 364 of BRV treatment. The proportion of patients who
achieved sustained response during the first year of adjunctive BRV
treatment was highest for patients with a BRV modal dose of > 100 to <
200 mg/day, followed by 200 mg/day, and was lowest for patients with
a BRV modal dose ≤ 100 mg/day.

KM estimates of the time to sustained 50%, 75%, and 100% response
in FBTCS during the first year of treatment overall and by BRV modal
dose category showed maintenance or improvements in the response to
BRV over time (Fig. 2). Sustained ≥ 50%, ≥ 75%, and 100% response in
FBTCS from day 1 of adjunctive BRV treatment during the entire first
year was estimated for 32.5%, 21.1%, and 15.0% of patients overall,
respectively.
The estimated proportion of patients achieving a sustained response
in FBTCS generally increased over time with 51.1% and 36.3% of pa
tients classified as ≥ 50% and ≥ 75% responders at day 364. The esti
mated proportion of patients achieving ≥ 50% or ≥ 75% sustained
response in FBTCS increased mainly during the first 6 months of treat
ment (more pronounced for ≥ 50% response). The estimated proportion

3.5. Freedom from FBTCS
Overall, 34.9% of patients were free from FBTCS for ≥ 1 year at any time
during the entire treatment period. For patients with at least 1 year of BRV
exposure (n = 193), overall 51.3% were free from FBTCS for ≥ 1 year
during the entire treatment period. This proportion was similar for patients
with a BRV modal dose of ≤ 100, > 100 to < 200, and 200 mg/day, with
52.5%, 55.9%, and 47.1% of patients free from FBTCS for ≥ 1 year,
respectively. For the patients who completed at least 1 year of BRV
5
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Fig. 2. Kaplan-Meier estimated time to sustained (A) ≥ 50%, (B) ≥ 75%, and (C) 100% response in FBTCS during the first year of BRV treatment: overall and by BRV
modal dosea (ES).
BRV, brivaracetam; ES, Efficacy Set; FBTCS, focal to bilateral tonic-clonic seizures.
a
The modal dose was based on the BRV dose taken during the first year of BRV exposure.
b
Kaplan-Meier estimates of the percentage of patients who achieved sustained response in FBTCS during the first year of BRV treatment. Patients who prematurely
discontinued the trial during the first year after BRV initiation were classified as nonresponders for the entire evaluation period.

treatment, 22.3% were free from FBTCS for at least 1 year from the first day
of BRV treatment. For patients with at least 5 years of BRV exposure (n =
43), 11.6% were free from FBTCS for at least 5 years from the first day of
BRV treatment (Supplementary Fig. 4).
Within each yearly completer cohort, the proportion of patients
reporting no FBTCS generally increased over time, and the proportion of
patients reporting one to two FBTCS generally decreased over time
(Fig. 3). In patients with at least 1 year of adjunctive BRV treatment,
22.8% of patients did not report FBTCS during the first year from the
first day of treatment, and this proportion ranged between 22.2% and
23.3% across the 1-, 2-, 3-, 4-, and 5-year completer cohorts. In patients
with at least 2 years of BRV treatment, 36.1%, 36.2%, 35.7%, and 34.9%
of patients in the 2-, 3-, 4-, and 5-year completer cohorts, respectively,
did not report FBTCS during the second year of BRV treatment.

3.6. Efficacy of BRV in FBTCS by number of prior or concomitant ASMs,
age at epilepsy onset, and epilepsy duration
Numerically higher FBTCS efficacy response was observed in pa
tients with fewer prior ASMs taken and discontinued before BRV initi
ation and in patients on one versus two concomitant ASMs at BRV
initiation (Supplementary Fig. 5). No differences were observed in the
median percentage reduction from baseline and 75% responder rate
based on age at epilepsy onset. However, a numerically lower 50%
responder rate and freedom from FBTCS for at least 1 year were
observed in patients with epilepsy onset at ≥ 20 years of age compared
to patients with earlier epilepsy onset. Patients with a longer epilepsy
duration showed a numerically higher efficacy response in most of the
outcomes assessed.
6
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Fig. 3. Proportion of patients with none or one to two FBTCS by yearly completer cohort and 52-week interval (ES).
ES, Efficacy Set; FBTCS, focal to bilateral tonic-clonic seizures.
a
Seizure frequency is standardized to a 28-day frequency.

Fig. 4. Mean number of days with FBTCS per patient per 8 weeks during the 8-week baseline and by 8-week intervals during BRV treatment (overall and by 50%
responder status) in patients with FBTCS during the core trial baseline (ES).
BL, baseline; BRV, brivaracetam; ES, Efficacy Set; FBTCS, focal to bilateral tonic-clonic seizures.

3.7. Number of days with FBTCS per 8-week intervals

initiation to first FBTCS (222.2 days; 95% CI: 161.3, 283.0) compared
with the mean time from last FBTCS to BRV initiation (17.5 days; 95%
CI: 14.9, 20.0) and from baseline start to first FBTCS (12.1 days; 95% CI:
10.5, 13.7) (Fig. 5).

In the overall population the mean number of days with FBTCS per
patient per 8-week interval was consistently substantially lower during
long-term adjunctive BRV treatment (range 0.9–3.5) compared with the
8-week baseline (7.0) (Fig. 4). The decrease in the mean number of days
with FBTCS was more pronounced in 50% responders. However, a
decrease was also observed in the patients who did not qualify as 50%
responders. Within each yearly completer cohort, the mean number of
days with FBTCS during adjunctive BRV treatment decreased compared
with baseline and was generally stable over time (Supplementary Fig. 6).

3.9. QOLIE-31-P scores
Patients who received BRV for ≥ 1 or ≥ 2 years showed improve
ments in the mean total QOLIE-31-P score, with a considerable mean
improvement at 2 years; 43.6% and 46.4% of patients showed clinically
meaningful improvements in total QOLIE-31-P score after 1 and 2 years
of treatment, respectively (Supplementary Fig. 7). The largest im
provements and > 50% of patients reporting a clinically meaningful
improvement in the QOLIE-31-P score were observed in the seizure
worry and daily activities/social functioning subscales after 1 and 2

3.8. Time to onset of FBTCS
Overall, there was a substantially higher mean time from BRV
7
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Fig. 5. Time to first FBTCS during baseline and
BRV treatment, and time from last FBTCS to
BRV initiation, in patients with FBTCS during
the core trial baseline (ES).
BRV, brivaracetam; CI, confidence interval; ES,
Efficacy Set; FBTCS, focal to bilateral tonicclonic seizures.
a
Measured from BRV initiation and censored at
the end of BRV treatment for patients who did
not report FBTCS.
b
Measured from baseline for patients random
ized to BRV in the core trial, and from across
baseline and the core trial for patients ran
domized to placebo in the core trial.

Measured from the start of baseline.

years of BRV treatment, and in the medication effects subscale after 2
years of BRV treatment. Clinically meaningful improvement in the
cognitive functioning subscale was reported by 45.8% and 47.2% of
patients at 1 and 2 years of BRV treatment, respectively.

[2.6%]), status epilepticus (eight [2.6%]), headache (five [1.6%]),
psychotic disorder (four [1.3%]), fatigue (three [1.0%]), epilepsy (three
[1.0%]), and suicide attempt (three [1.0%]).
Serious TEAEs reported by four or more patients were convulsion (10
[3.2%]), status epilepticus (nine [2.9%]), suicide attempt (five [1.6%]),
epilepsy (four [1.3%]), psychotic disorder (four [1.3%]), and hypona
tremia (four [1.3%]).
The most common (≥ 1% of patients) TEAEs leading to permanent
discontinuation of BRV were dizziness (five [1.6%]), suicide attempt
(four [1.3%]), and convulsion (three [1.0%]).
Psychiatric TEAEs and TEAEs potentially associated with behavioral
disorders were reported by 101 (32.3%) and 42 (13.4%) patients,
respectively, and were most commonly (≥ 2% of all patients) irritability
(6.7%), insomnia (6.4%), depression (6.1%), anxiety (5.8%), and
aggression (3.8%). During long-term adjunctive BRV treatment (up to
11.3 years) in adults with FBTCS, 11 (3.5%) patients died (SS: MedDRA
Preferred Terms: death [two patients], cardio-respiratory arrest, sudden

3.10. Tolerability
In the SS (n = 313), 278 (88.8%) patients reported at least one TEAE,
88 (28.1%) patients had a serious TEAE, and 55 (17.6%) discontinued
due to a TEAE (Table 2). The most frequent TEAEs (≥ 10% of patients)
were headache (18.2%), dizziness (14.4%), somnolence (14.4%), fa
tigue (11.8%), and convulsion (10.5%). One hundred and seventy
(54.3%) patients had a TEAE that was considered drug-related by the
investigator, most commonly (≥ 5% of patients) somnolence (38
[12.1%]), dizziness (28 [8.9%]), fatigue (27 [8.6%]), and headache (19
[6.1%]). At least one severe TEAE was reported by 83 (26.5%) patients,
and the most common (≥ 1% of patients) were convulsion (eight

Table 2
Incidence of TEAEs with onset during the treatment period overall and by BRV modal dose category (SS).
Patients, n (%)

BRV Overall (N = 313)

BRV ≤ 100 mg/day (n = 99)

BRV > 100 to < 200 mg/day (n = 94)

BRV 200 mg/day (n = 120)

Any TEAEs
Drug-related TEAEs
Serious TEAEs
Severe TEAEs
Discontinuations due to TEAEs
Deaths

278 (88.8)
170 (54.3)
88 (28.1)
83 (26.5)
55 (17.6)
11 (3.5)

90 (90.9)
68 (68.7)
30 (30.3)
29 (29.3)
28 (28.3)
5 (5.1)

82 (87.2)
43 (45.7)
26 (27.7)
20 (21.3)
9 (9.6)
3 (3.2)

106 (88.3)
59 (49.2)
32 (26.7)
34 (28.3)
18 (15.0)
3 (2.5)

TEAEsa occurring in ≥ 10% of all patients
Headache
57 (18.2)
Dizziness
45 (14.4)
Somnolence
45 (14.4)
Fatigue
37 (11.8)
Convulsion
33 (10.5)

21 (21.2)
12 (12.1)
16 (16.2)
12 (12.1)
14 (14.1)

16 (17.0)
9 (9.6)
9 (9.6)
9 (9.6)
13 (13.8)

20 (16.7)
24 (20.0)
20 (16.7)
16 (13.3)
6 (5.0)

TEAEs classified as psychiatric disordersa
At least one
101 (32.3)
Drug-related
62 (19.8)
Leading to discontinuation
20 (6.4)

38 (38.4)
32 (32.3)
12 (12.1)

29 (30.9)
16 (17.0)
2 (2.1)

34 (28.3)
14 (11.7)
6 (5.0)

TEAEs potentially associated with behavioral disordersb
At least one
42 (13.4)
Drug-related
26 (8.3)
Leading to discontinuation
7 (2.2)

19 (19.2)
15 (15.2)
4 (4.0)

8 (8.5)
4 (4.3)
1 (1.1)

15 (12.5)
7 (5.8)
2 (1.7)

TEAEs classified as psychiatric disordersa and potentially associated with behavioral disordersb reported by ≥ 2% of all patients
Irritability
21 (6.7)
8 (8.1)
4 (4.3)
Insomnia
20 (6.4)
9 (9.1)
4 (4.3)
Depression
19 (6.1)
7 (7.1)
6 (6.4)
Anxiety
18 (5.8)
5 (5.1)
7 (7.4)
Aggression
12 (3.8)
7 (7.1)
3 (3.2)

SS, Safety Set; TEAE, treatment-emergent adverse event.
a
Preferred Term (Medical Dictionary for Regulatory Activities, Version 15.0).
b
Medical Dictionary for Regulatory Activities Preferred Terms selected by medical review.
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9 (7.5)
7 (5.8)
6 (5.0)
6 (5.0)
2 (1.7)
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death, SUDEP, head injury, intentional overdose, road traffic accident,
central nervous system lesion, completed suicide, and brain hypoxia
[one patient each]). Three deaths were considered drug-related by the
investigator (MedDRA Preferred Terms: death, completed suicide, and
brain hypoxia), and all other deaths were not considered drug-related.
In patients without a history of FBTCS the incidence of new-onset
FBTCS during BRV treatment was low; 25/405 (6.2%) patients re
ported their first FBTCS during BRV treatment, with a mean time from
BRV initiation of 463.6 days (95% CI: 246.2, 681.0; median: 212.0
days); 3/405 (0.7%) patients reported a TEAE of grand mal convulsion
during BRV treatment at day 12, 367, and 1123 after BRV initiation,
respectively.

treatment period (1 year).
For patients who completed ≥ 1 year of adjunctive BRV treatment,
analyses were performed on early completer cohorts (1-year to 5-year
completer cohorts), where the same patients were followed from the
beginning to the end of the particular period (during the overall period
and by 12-week intervals). This approach, ensuring no within-cohort
selection bias (Ben-Menachem et al., 2003), showed that the FBTCS
response (median percentage reduction from baseline, 50%, and 75%
responder rates) in each cohort was maintained over time.
In the overall population, the time to sustained response in FBTCS
during the first year of treatment tended to be lower for patients who
received a modal dose of BRV ≤ 100 mg/day. However, when consid
ering the patients with a modal BRV dose ≤ 100 mg/day who completed
at least 1 year of treatment, the efficacy outcomes were generally similar
(or numerically higher) to those observed in patients with BRV modal
doses > 100 mg/day. The disposition data during the first year of BRV
treatment showed that a higher proportion of patients with a BRV modal
dose ≤ 100 mg/day compared to those with a BRV modal dose > 100 to
< 200 mg/day and 200 mg/day discontinued treatment due to any
reason (53.5% vs 18.1% and 26.1%), due to AE (20.9% vs 4.8% and
10.4%), or due to lack of efficacy (14.0% vs 2.4% and 5.2%). These data
suggest that the patients treated with a BRV modal dose ≤ 100 mg/day
consisted of patients that were more sensitive to AEs and/or were more
difficult to control, and patients who responded to relatively low BRV
doses.
Several studies have identified that the presence and frequency of
generalized tonic-clonic seizures (GTCS) is the most important risk
factor for SUDEP (Sveinsson et al., 2020), with an increasing number of
GTCS per year associated with a statistically significant increased risk
for SUDEP (Hesdorffer et al., 2011; Ryvlin et al., 2019). Patients with
three or more GTCS per year have a 15-fold increased risk of SUDEP
(Harden et al., 2017). In this post hoc analysis, 34.9% of patients were
free from FBTCS for ≥ 1 year at any time during the entire treatment
period; in patients who completed at least 1 year of adjunctive BRV
treatment (median baseline FBTCS frequency of approximately two per
28 days), 51.3% were free from FBTCS for ≥ 1 year during the entire
treatment period; approximately 23% were free from FBTCS during the
first year (from the first day of BRV treatment), and approximately 36%
did not report FBTCS during the second year of BRV treatment. There
fore, the maintenance or improvement in the proportion of patients not
reporting FBTCS over time presented in this pooled analysis supports the
beneficial effects of BRV over time.
The occurrence of GTCS has been identified as one of the factors
predicting poor HRQoL (de la Loge et al., 2016), and reducing the fre
quency of FBTCS has the potential to improve the overall HRQoL of
patients with epilepsy (Sperling et al., 2016; Taylor et al., 2011). In this
analysis in patients with FBTCS, long-term adjunctive BRV treatment
was generally associated with improvement in the overall HRQoL. The
largest improvements in the QOLIE-31-P scores after 1 and 2 years of
adjunctive BRV treatment were observed in the subscales sensitive to
efficacy (seizure worry and daily activities/social functioning), reflect
ing the long-term efficacy of adjunctive BRV. Clinically meaningful
improvement was also reported by 52.8% of patients in the medication
effects subscale after 2 years of treatment, reflecting a low level of
tolerability issues with BRV treatment. For the QOLIE-31-P total score
and subscale results, the mean change from baseline and the proportion
of patients with a meaningful improvement, are similar to those re
ported for adults with uncontrolled focal onset (partial) seizures
receiving adjunctive BRV in a pooled analysis of Phase IIb/III and
long-term follow-up trials (Toledo et al., 2016), as well as in an interim
analysis of an ongoing prospective, non-interventional post-marketing
study on patients in Europe (EP0077; NCT02687711) (Steinhoff et al.,
2020). These QOLIE-31-P data provide further evidence that long-term
treatment with adjunctive BRV in patients with FBTCS leads to im
provements in quality of life measures.
In this post hoc analysis, at least one TEAE was reported by 88.8% of

4. Discussion
The results of this post hoc analysis of long-term (up to 11.3 years)
pooled data indicate the long-term sustained efficacy of adjunctive BRV
in reducing the frequency of FBTCS in adults. In patients with FBTCS,
long-term BRV treatment was generally well tolerated and associated
with improvement in the overall HRQoL. The results from this analysis
extends the previous findings on the short-term (12-week) efficacy and
tolerability of adjunctive BRV in adults with FBTCS (Klein et al., 2020a;
Moseley et al., 2016) by reporting long-term efficacy, tolerability, and
HRQoL data.
Although randomized, controlled trials are the standard for evalu
ating the efficacy and safety of new drugs (Maguire et al., 2008),
open-label, long-term follow-up trials can provide valuable information
in a setting that more closely emulates clinical practice regarding
long-term tolerability and efficacy of ASMs (Hemming et al., 2008;
Maguire et al., 2008; Mohanraj and Brodie, 2003). The results from this
post hoc analysis therefore provide important data on the long-term
efficacy and tolerability of BRV in patients with FBTCS.
The median BRV treatment duration was 2.5 years (range < 0.1–11.3
years) and the estimated proportion of patients remaining on BRV
treatment at 1, 3, and 5 years, was 69.3%, 48.2%, and 37.3%, respec
tively. The same proportion of patients discontinued due to lack of ef
ficacy (18.3%) or AE (18.3%). The estimated proportion of patients not
discontinuing BRV due to lack of efficacy or AE was 80.0%, 63.9%, and
57.2% at 1, 3, and 5 years, respectively. As 11.6% of patients dis
continued treatment due to consent withdrawn, it cannot be ruled out
that some of these patients may have discontinued BRV treatment due to
reasons related to lack of efficacy or AEs. Although this is a potential
limitation, considering the conservative approach applied in assessing
the time to BRV discontinuation (measured from the first day of active
treatment whether during the core trial or at long-term follow-up trial
entry), these data support the long-term effectiveness of BRV in adults
with FBTCS.
In order to evaluate the efficacy response during adjunctive BRV
treatment over time, different approaches were applied. The time to
sustained FBTCS response (50%, 75%, and 100%) during the first year of
treatment estimated the proportion of patients who achieved a sustained
(rather than transient) response and did not discontinue BRV during the
first year of treatment (Klein et al., 2017, 2020a). In the population with
FBTCS analyzed, approximately one-third of patients with FBTCS
treated with BRV achieved sustained ≥ 50% response, one-fifth achieved
sustained ≥ 75% response, and one-seventh achieved sustained 100%
response in FBTCS on the first-treatment day through the entire first year
of treatment. For time to sustained ≥ 50% response during the first year,
the proportion of patients achieving a sustained response increased
mainly during the first 6 months of treatment, with a smaller further
increase during the second 6 months. This result suggests that the ma
jority of patients who will achieve a sustained ≥ 50% response during
the first year of BRV treatment will reach this outcome during the first 6
months of treatment. These data further support previous observations
that efficacy of BRV occurs early after BRV is initiated (Klein et al., 2017,
2020a; Klein et al., 2020b) and provide data over a longer BRV
9
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patients with FBTCS, 17.6% of patients discontinued due to a TEAE, and
the most commonly reported TEAEs (≥ 10%) were headache, dizziness,
somnolence, fatigue, and convulsion. Therefore, the tolerability profile
of BRV in this subpopulation with FBTCS was generally similar to that
reported in a pooled interim analysis of Phase IIb/III and long-term
follow-up trials of adjunctive BRV in patients with focal or generalized
seizures (Toledo et al., 2016).
Behavioral TEAEs such as aggression and anger have been often
associated with ASM use (Chen et al., 2017). During long-term BRV
treatment of patients with FBTCS, the incidence of TEAEs potentially
associated with behavioral disorders was generally low (13.4%), and
was comparable with the incidence reported in pooled open-label,
long-term trials of BRV in adults with epilepsy (15.1%) (UCB Pharma,
2020).
Some caution is recommended in interpreting these data, as this was
a post hoc analysis of data pooled across double-blind and single-arm
open-label, long-term follow-up trials without a comparator group. As
BRV was used as an adjunctive treatment and in the long-term follow-up
trials a flexible dose regimen of BRV and the concomitant ASM(s) was
applied, the potential contribution of adaptations in the treatment
regimen of the concomitant ASM(s) to the efficacy outcomes observed
and the TEAEs reported cannot be completely ignored.
In summary, long-term adjunctive BRV treatment was generally well
tolerated and provided sustained long-term reduction in the frequency
of FBTCS in adults, with 22.8% of patients who completed at least 1 year
of BRV treatment and did not report FBTCS during the first year from the
first day of BRV treatment.

investigators and their teams who contributed to these trials. The au
thors would like to acknowledge Ciara Duffy, PhD (Evidence Scientific
Solutions, London, UK) for writing assistance, which was funded by UCB
Pharma. Publication coordination was provided by Fabien Debailleul,
PhD (UCB Pharma, Brussels, Belgium) and Kathleen Richards, PhD (UCB
Pharma, Smyrna, GA, USA).
Appendix A. Supplementary data
Supplementary material related to this article can be found, in the
online version, at doi: https://doi.org/10.1016/j.eplepsyres.2021.10
6694.
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